Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells

Journal of Investigative Dermatology

Volumn 127, Issue 10, 2007, Pages 2425-2437

  Braun, Frank K ^a   Fecker, Lothar F ^a   Schwarz, Constanze ^a   Walden, Peter ^a   Assaf, Chalid ^a   Dürkop, Horst ^a   Sterry, Wolfram ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; DEATH RECEPTOR; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PROTEIN BID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BID PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR BIOPSY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; T CELL LEUKEMIA; TUMOR CELL LINE;

AGED; ANTIGENS, CD95; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 10; CELL LINE, TUMOR; FEMALE; HUMANS; LEUKEMIA, T-CELL, ACUTE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848902287     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700868     Document Type: Article

References (69)

1. Ashkenazi A (2002) Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer 2:420-30
2. Bassan R, Gatta G, Tondini C, Willemze R (2004) Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol 50:223-61
3. Burg G, Kempf W, Cozzio A, Feit J, Willemze R, Jaffe S et al. (2005) WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 32:647-74
4. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai lM et al. (2006) The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 119:944-54
5. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM et al. (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419:395-9
6. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S et al. (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-29
7. Dereure O, Levi E, Vonderheid EC, Kadin ME (2002) Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 118:949-56
8. Dereure O, Portales P, Clot J, Guilhou JJ (2000) Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 143:1205-10
9. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331-40
10. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G (1998) Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92:252-8
11. Dummer R, Michie SA, Kell D, Gould JW, Haeffner AC, Smoller BR et al. (1995) Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 22:11-7
12. Dutton A, Young LS, Murray PG (2006) The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 10:27-35
13. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22:9131-41
14. Fischer U, Stroh C, Schulze-Osthoff K (2006) Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene 25:152-9
15. Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:209-14
16. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-9
17. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M et al. (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130:501-10
18. Giri DK, Aggarwal BB (1998) Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273:14008-14
19. Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J (2005) Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 579:6217-22
20. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC (1981) Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 154:1403-18
21. Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92:1240-51
22. Guitart J (2006) Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Semin Oncol 33:S17-20
23. Gupta S, Bi R, Gollapudi S (2005) Central memory and effector memory subsets of human CD4(+) and CD8(+). Ann N Y Acad Sci 1050:108-114
24. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C et al. (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10:356-64
25. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11:S193-206
26. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD et al. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88-93
27. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, Thestrup-Pedersen K (1992) Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 28A:161-7
28. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W (1987) A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279:293-8
29. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P et al. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639-46
30. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789-95
31. Kurbanov BM, Geilon CC, Fecker LF, Orfanos CE, Eberle J (2005) Efficient TRAIL-RI/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related aptosis-inducing ligand (TRAIL). J Invest Dermatol 125:1010-19
32. Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV (2006) SAHAsensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer 119:221-8
33. Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J Cell Sci 118:265-7
34. Li-Weber M, Krammer PH (2003) Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15:145-57
35. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH et al. (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21: 6809-18
36. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M et al. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199:1041-52
37. Minowada J, Onuma T, Moore GE (1972) Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49:891-5
38. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005) Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84:1-12
39. Nagasawa T, Takakuwa T, Takayama H, Dong Z, Miyagawa S, Itami S et al. (2004) Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology 67:130-4
40. Oehadian A, Koide N, Mu MM, Hassan F, Islam S, Yoshida T et al. (2005) Interferon (IFN)-beta induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Lett 225:85-92
41. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806-9
42. Olsen EA (2003) Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 16:311-21
43. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Drakos E et al. (2006) c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 107:2544-7
44. Peter ME, Legembre P, Barnhart BC (2005) Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755:25-36
45. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al. (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430-41
46. Reed JC (2004) Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park) 18:11-20
47. Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106:408-18
48. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47
49. Riedl SJ, Shi Y (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5:897-907
50. Scherer WF, Syverton JT, Gey GO (1953) Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97: 695-710
51. Schneider U, Schwenk HU, Bornkamm G (1977) Characterization of EBVgenome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19:621-6
52. Shankar S, Chen X, Srivastava RK (2005a) Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62:165-86
53. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK (2005b) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125-1138
54. Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN et al. (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094-9
55. Smith JL, Clein GP, Barker CR, Collins RD (1973) Characterisation of malignant mediastinal lymphoid neoplasm (Sternberg sarcoma) as thymic in origin. Lancet 1:74-7
56. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW et al. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618-24
57. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G et al. (2006) Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354-63
58. Starkebaum G, Loughran TP, Jr, Waters CA, Ruscetti FW (1991) Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor. Int J Cancer 49:246-53
59. Su H, Bidere N, Zheng L, Cubre A, Sakai K, Dale J et al. (2005) Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 307:1465-8
60. van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP (2002) A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62:5389-92
61. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-63
62. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M et al. (1999) Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98:47-58
63. Wang S, El Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628-33
64. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85
65. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM, Mizuguchi J (2005) Requirement of c-Jun NH2-terminal kinase activation in interferonalpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 310:10-21
66. Zhang C, Richon V, Ni X, Talpur R, Duvic M (2005) Selective induction of apoptosis by histone deacetylase inhibitor suberoylanilide hydroxamic acid in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-52
67. Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Dobbeling U (2003a) Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 200:249-54
68. Zhang XR, Zhang LY, Devadas S, Li L, Keegan AD, Shi YF (2003b) Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ 10:203-10
69. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313-9